Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 known ✓ | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B known ✓ | P08514 | 1/20 | 0.45 |
| ▸ | CA2 known ✓ | P00918 | 4/20 | 0.43 |
| ▸ | MMP13 known ✓ | P45452 | 2/20 | 0.41 |
| ▸ | MMP1 known ✓ | P03956 | 1/20 | 0.41 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 4/20 | 0.56 |
| ▸ | MMP9 | P14780 | 2/20 | 0.56 |
| ▸ | PLAU | P00749 | 4/20 | 0.47 |
| ▸ | HPN | P05981 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11406948 | 1.00 | MMP2 (0.56) | MMP2MMP9PLAUHPNITGB3 | |
| SCHEMBL200247 | 0.99 | MMP2 (0.57) | MMP2MMP9PLAUHPNITGB3 | |
| SCHEMBL200245 | 0.99 | MMP2 (0.57) | MMP2MMP9PLAUHPNITGB3 | |
| Hydrochloric Acid SCHEMBL15537019 | 0.96 | MMP2 (0.55) | MMP2MMP9PLAUHPNITGB3 | |
| SCHEMBL1305743 | 0.88 | MMP2 (0.56) | MMP2MMP9PLAUHPNITGB3 | |
| SCHEMBL1305745 | 0.88 | MMP2 (0.56) | MMP2MMP9PLAUHPNITGB3 | |
| Hydrochloric Acid SCHEMBL1499337 | 0.87 | MMP9 (0.65) | MMP2MMP9PLAUHPNITGB3 | |
| Hydrochloric Acid SCHEMBL14059214 | 0.87 | MMP9 (0.65) | MMP2MMP9PLAUHPNITGB3 | |
| SCHEMBL5490595 | 0.86 | PLAU (0.45) | MMP2MMP9PLAUHPNITGB3 | |
| Hydrochloric Acid SCHEMBL9087107 | 0.86 | MMP9 (0.74) | MMP2MMP9PLAUHPNITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2722054-B1 | Methods and compositions for oral administration of proteins | ORAMED PHARMACEUTICALS INC (IL) | 2018-03-21 | — | — | EP | claimed |
| EP-2722054-A1 | Methods and compositions for oral administration of proteins | Oramed Pharmaceuticals Inc. (IL) | 2014-04-23 | — | — | EP | claimed |
| EP-1933862-A2 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS | Oramed Pharmaceuticals Inc. (IL) | 2008-06-25 | — | — | EP | claimed |
| US-20070087957-A1 | Methods and compositions for oral administration of proteins | ORAMED PHARMACEUTICALS INC. (IL) | 2007-04-19 | — | — | US | claimed |
| WO-2007029238-A2 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS | ORAMED PHARMACEUTICALS, INC. (IL) | 2007-03-15 | — | — | WO | claimed |
| US-20060182722-A1 | Methods and materials for isolating isogenic islet cells | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2006-08-17 | — | — | US | claimed |
| EP-3873495-B1 | METHODS AND COMPOSITIONS FOR TREATMENT OF TYPE 1 DIABETES USING FIBROBLASTS AS FACILITATORS OF ISLET ENGRAFTMENT | FIGENE LLC (US) | 2024-06-26 | — | — | EP | disclosed |
| CN-118019522-A | Pharmaceutical composition comprising a large physiologically active substance and an excipient | D&D制药技术股份有限公司 | 2024-05-10 | — | — | CN | disclosed |
| US-20240115619-A1 | TREATMENT OF DIABETES BY ENHANCEMENT OF PANCREATIC ISLET ENGRAFTMENT THROUGH REGENERATIVE IMMUNE MODULATION | CREATIVE MEDICAL TECHNOLOGIES, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| EP-4257143-A2 | METHODS AND COMPOSITIONS FOR TREATMENT OF TYPE 1 DIABETES USING FIBROBLASTS AS FACILITATORS OF ISLET ENGRAFTMENT | Figene, LLC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20230240997-A1 | METHOD OF TREATING CANCER | THERASYN SENSORS INC (US) | 2023-08-03 | — | — | US | disclosed |
| US-11660327-B2 | Methods and compositions for oral administration of proteins | ORAMED LTD. (IL) | 2023-05-30 | — | — | US | disclosed |
| US-20220160839-A1 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS | ORAMED PHARMACEUTICALS, INC. (IL) | 2022-05-26 | — | — | US | disclosed |
| WO-2007029238-A2 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS | ORAMED PHARMACEUTICALS, INC. (IL) | 2007-03-15 | — | — | WO | disclosed |
| US-7150988-B2 | Controlling proteolytic action in natural rubber latex | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2006-12-19 | — | — | US | disclosed |
| US-20060182722-A1 | Methods and materials for isolating isogenic islet cells | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2006-08-17 | — | — | US | disclosed |
| WO-2006063810-A1 | CONTROLLING PROTEOLYTIC ACTION NATURAL RUBBER LATEX | ROCHE DIAGNOSTICS GMBH (DE) | 2006-06-22 | — | — | WO | disclosed |
| US-20060127970-A1 | Controlling proteolytic action in natural rubber latex | ALLERGEN REDUCTION, INC. | 2006-06-15 | — | — | US | disclosed |
| EP-0624641-B1 | Thermostable nucleic acid polymerase | HOFFMANN LA ROCHE (CH) | 2000-12-13 | — | — | EP | disclosed |
| EP-0624641-A2 | Thermostable nucleic acid polymerase | F. HOFFMANN-LA ROCHE AG (CH) | 1994-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060182722-A1 | Methods and materials for isolating isogenic islet cells | IAPP, RNASE1, PNLIP | ITGB3 238/4885ITGA2B 566/4885CA2 3758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.